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Amylin (islet amyloid polypeptide) and amyloid-beta (Aβ) protein, which are deposited
within pancreatic islets of diabetics and brains of Alzheimer’s patients respectively, share
many biophysical and physiological properties. Emerging evidence indicates that the amylin
receptor is a putative target receptor for the actions of human amylin and Aβ in the brain.
The amylin receptor consists of the calcitonin receptor dimerized with a receptor activity-
modifying protein and is widely distributed within central nervous system. Both amylin and
Aβ directly activate this G protein-coupled receptor and trigger multiple common intracel-
lular signal transduction pathways that can culminate in apoptotic cell death. Moreover,
amylin receptor antagonists can block both the biological and neurotoxic effects of human
amylin and Aβ. Amylin receptors thus appear to be involved in the pathophysiology of
Alzheimer’s disease and diabetes, and could serve as a molecular link between the two
conditions that are associated epidemiologically.
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INTRODUCTION
Both Alzheimer’s disease (AD) and type-2 diabetes mellitus
(T2DM) are chronic, age-related diseases that share common
clinical and biochemical features (Selkoe, 1997; Hoppener et al.,
2000; Götz et al., 2009; Wolfson et al., 2009; Tacutu et al., 2010).
In addition to epidemiological links between the two diseases
(Luchsinger, 2010), insulin-resistant T2DM has been identified
as a risk factor for AD (Craft, 2007). Dysregulation of insulin and
IGF-1 (insulin growth factor-1) receptors has been observed in AD
patient brains (Moloney et al., 2010). Impairment of these recep-
tors contributes to increased amyloid-beta (Aβ) protein aggrega-
tion, subsequent synaptic loss, and cognitive impairment (Zhao
et al., 2009). T2DM and AD are pathologically characterized by
presence of insoluble protein aggregates resulting in formation
and deposition of amylin in T2DM and Aβ in AD respectively
(Westermark et al., 2011; Abedini and Schmidt, 2013). Amylin
or islet amyloid polypeptide (IAPP) is a 37-amino acid pep-
tide first isolated from amyloid-rich pancreatic extracts of type-2
diabetic patients (Cooper et al., 1987). This misfolded protein
forms elongated fibrils with spines consisting of many-stranded β
sheets and enters the amyloid state (Eisenberg and Jucker, 2012).
Amylin is also deposited in human brains in T2DM with demen-
tia and AD patients (Jackson et al., 2013). Both amylin and Aβ
directly activate amylin receptors, and the biological effects of
these two peptides and their neurotoxic actions can be blocked
with specific amylin receptor antagonists (Jhamandas and Mac-
Tavish, 2004; Jhamandas et al., 2011). These observations have
raised further questions concerning the relationship, at a molecu-
lar level, between these two different common clinical conditions
and the role that the amylin receptor may play as a common
pathological link.
AMYLIN RECEPTORS
Amylin receptors consist of heterodimerized complexes of the cal-
citonin receptor (CTR) interacting with one of receptor activity-
modifying proteins (RAMPs). CTR is a seven transmembrane-
domain Class B G protein-coupled receptor. The RAMP is a
single-domain protein, and not a receptor itself, with three cur-
rently known subtypes named RAMP1–3. These RAMPs can het-
erodimerize with CTR to form a subset of amylin receptors
(AMY1–3) or in combination with calcitonin receptor-like recep-
tor (CLR) form either calcitonin gene-related peptide (CGRP) or
adrenomedullin receptors (Hay and Poyner, 2013). The physiolog-
ical roles ascribed to amylin are mediated via the amylin receptors
(Muff et al., 1999). Distribution of amylin and its receptors is fairly
widespread in the brain. The most investigated of amylin functions
in the brain relate to control of energy homeostasis and body fluid
balance through amylin receptors (Lutz, 2012). In rat, the amylin
neural circuit includes the area postrema, a structure devoid of
the blood brain barrier, the nucleus of the solitary tract, the lat-
eral parabrachial nucleus, and the central nucleus of the amygdala
(Roth et al., 2009). In postpartum rats, amylin levels are signifi-
cantly elevated in the preoptic nuclei suggesting that this peptide is
also involved in maternal physiological functions (Dobolyi, 2009).
However, its role in cognitive function is incompletely understood
in spite of the localization of this peptide in many areas related to
memory and learning. At present, there is no information available
on age-related changes in the expression of amylin or its receptors
in the brain.
Aβ AND ALZHEIMER’S DISEASE
The amyloid plaque is one of core pathological hallmarks in AD
(Hardy, 2006; Ballard et al., 2011). Aβ is a 40- or 42-amino acid
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peptide cleaved from a larger precursor, amyloid precursor pro-
tein (APP), by the actions of β- and γ-secretases. Aβ can form
monomers, oligomers, or fibrils. Small soluble oligomers of Aβ
are deemed to be more toxic than mature fibrils (Ballard et al.,
2011). AD is a complex neurodegenerative disease caused by mul-
tiple dysregulated neurobiological networks and cellular functions,
neuronal, and memory loss. It is clear that soluble oligomeric Aβ
plays a key role in the pathogenesis of AD, although as a therapeu-
tic target in this condition, it has posed significant challenges, and
as yet, is of unproven benefit.
AMYLIN AND TYPE-2 DIABETES
Amylin is co-secreted with insulin by pancreatic beta-cells but is
greatly decreased in diabetic individuals following food intake. It
has the propensity to form membrane permeant toxic oligomers
and aggregate into fibrils in much the same way as Aβ. These toxic
amylin oligomers contribute to pancreatic beta-cell loss in T2DM
(Haataja et al., 2008). The effects of amylin on glucose metabolism
and food intake are mediated by the peripheral and central mech-
anisms (Young, 2005). Amylin concentration is only 1–2% that
of insulin and concurrently increases with insulin after glucose
stimulation. It inhibits glucagon release and influences insulin
secretion in a concentration-dependent manner (Akesson et al.,
2003). Amylin also inhibits gastric emptying in a manner similar
to glucagon-like peptide-1 (GLP1) and decreases food intake via
central autonomic mechanisms (Rushing et al., 2000). Although
many of amylin functions are still not fully understood, there are
two plausible physiological roles of amylin that are of particular
interest. The first relates to its function as an auto- or paracrine
molecule in the islets of Langerhans, and the other is its role as a
neurohormone with effects on the central nervous system (CNS)
(Westermark et al., 2011). The amylin fibrillogenicity is species
dependent. Although there is only a six amino acid difference
between human and rat amylin, human amylin, but not rat, is
amyloidogenic and demonstrates neurotoxic properties (Lim et al.,
2008).
AMYLIN AND Aβ
Although there is no sequence homology between Aβ and human
amylin, both aggregate and form amyloid fibrils. In this process,
they share the same important features which include sequence-
specific aggregation with oligomeric intermediates as precursors to
the aggregated state and the physical state of inclusion bodies. The
amyloid fibrils are typically unbranched, variable in length, poly-
morphic, and form crossed β-sheet structures (Mitraki, 2010; Abe-
dini and Schmidt, 2013). The amyloid plaque formation could be a
dynamic process between protein monomers, oligomers, and fib-
rils. Amyloid fibrils can be an integral part of normal cellular phys-
iology and serve as storage reservoirs for peptide hormones within
secretory granules (Maji et al., 2009). Although Aβ or amylin
insoluble fibrils may play some physiological/pathophysiological
roles, it is the soluble oligomeric intermediates that are believed
to represent the primary toxic species of amyloids (Hardy and
Selkoe, 2002). Many soluble oligomers from different proteins
(including Aβ, amylin, prion protein, alpha-synuclein) display
a common conformation-dependent structure that is unique to
soluble oligomers regardless of sequence. The oligomer toxicity
is inhibited by oligomer-specific antibodies, which suggests that
different types of soluble amyloid oligomers have a common struc-
ture and share a common mechanism of toxicity (Kayed et al.,
2003). Interestingly, human amylin shows strikingly similar neu-
rotoxicity profiles with Aβ (May et al., 1993; Lim et al., 2008,
2010). Amylin receptor antagonists, AC187 or AC253, attenuate
or block Aβ- and amylin-induced neurotoxicity, potassium chan-
nel activity, and activation of pro-apoptotic genes (Jhamandas
et al., 2003, 2011; Jhamandas and MacTavish, 2004). Downreg-
ulation of amylin receptor gene expression using siRNA atten-
uates the oligomerized Aβ-induced toxicity (Jhamandas et al.,
2011). Moreover, in AD transgenic model mice (TgCRND8) which
over-express APP, amylin receptor expression in the brain was
up-regulated in an age-dependent manner within specific brain
regions that also demonstrated an increased amyloid burden
(Jhamandas et al., 2011). Aβ, in a manner identical to human
amylin, can directly activate AMY3 to raise cyclic adenosine
monophosphate (cAMP), increase intracellular calcium, and PKA
and MAPK phosphorylation (Fu et al., 2012). Furthermore,AC253
acting via AMY3 receptors, can re-establish the long-term poten-
tiation (LTP) in hippocampus of AD mice (TgCRND8) (Kimura
et al., 2012). Thus, many of the effects of Aβ, at a cellular level,
appear to be expressed via the amylin receptor and such observa-
tions support the presence of a direct interaction between oligomer
Aβ and amylin receptors.
INSULIN, IDE, IGF-1 AND 2, AND INSULIN RECEPTORS IN
DIABETES AND ALZHEIMER’S DISEASE
Recently, based on evidence of shared pathophysiology between
AD and T2DM, AD has been proposed to represent “Type 3 dia-
betes” (Steen et al., 2005). Several candidate proteins have been
proposed to bridge the pathophysiological link between the two
conditions. The major mechanism through which T2DM may
influence AD includes central insulin resistance, which leads to
reduced sensitivity to insulin in the brain, resulting in hyperin-
sulinemia, impaired insulin receptor (IR) signaling, and glucose
toxicity (Freude et al., 2009; Han and Li, 2010). T2DM mediated
hyperinsulinemic/hypoglycemic episodes may produce long-term
changes in brain vasculature, cellular toxicity including inflam-
mation and oxidative stress, alternations in Aβ levels, tau phos-
phorylation, neurodegeneration, and cognitive impairment, thus
facilitating AD onset. It is clear that insulin and IGF-1 have intense
effects in the CNS, acting as neuromodulators to influence release
and uptake of neurotransmitters, energy homeostasis, neuronal
survival, as well as learning and memory (Bosco et al., 2011). There
is a decrease in insulin mRNA and protein levels (Steen et al., 2005)
and a marked disturbance of IR and IGF-1R signaling in the CNS
of AD patients (Frölich et al., 1998). Post-mortem examination
of brains from patients with AD revealed substantial downregula-
tion of IR, IGF-1R, and insulin receptor substrate (IRS) proteins
(Squire, 1986), that correlate with the severity and progression of
neurodegenerative changes in this condition (Frölich et al., 1998).
Insulin resistance has been postulated to interfere with Aβ catab-
olism and clearance in AD pathogenesis (Qiu and Folstein, 2006).
Impairment in IGF-1 is linked to Aβpathology and IGF-1 increases
Aβ clearance from brain in AD animal models (Carro et al., 2006).
IDE is the chief enzyme that degrades excess insulin and other

























































Fu et al. Amylin receptor in Alzheimer’s and diabetes
substrates, including Aβ (Farris et al., 2003). The imbalance of the
substrates could affect the IDE-induced degradation process, and
in the process influence the pathogenesis of AD or T2DM. Increas-
ing the amount of insulin appears to both stimulate Aβ secretion
and also inhibit the IDE enzymatic degradation of extracellular
Aβ, thus resulting in increased Aβ neurotoxicity (Qiu and Folstein,
2006). Additionally, IDE knockout mice experience decreased Aβ
degradation, hyperinsulinemia, and hyperglycemia (Farris et al.,
2003).
In summary, amyloid formation is a fundamental process
observed in many protein misfolding diseases including AD
and T2DM. Increasing evidence indicates that the intermediate
oligomers from different proteins form common conformation-
dependent structures that play primary pathological roles in neu-
rodegenerative conditions. One common target for the soluble
oligomers Aβ and human amylin is the amylin receptor. Figure 1
summarizes our perspective on the commonality of structure-
functional relationships between the two proteins. Activation of
the amylin receptor by the two peptides can modulate activity
of individual neurons at a cellular and synaptic level, but more
chronic exposure to these peptides results in activation of sig-
nal transduction pathways that culminate in apoptotic cell death.
Currently, the treatment of AD remains a serious and important
public health concern. Beyond symptomatic treatment, there is as
yet no effective intervention for AD. Targeting amylin receptors
using amylin receptor antagonists to block the deleterious effects
of Aβ and human amylin could represent a novel therapeutic
FIGURE 1 | Summary of human amylin and amyloid-beta (Aβ)
interactions with the amylin receptor (AMY3) and functional
consequences of such interactions at the peripheral and central levels.
approach to treating AD and T2DM, conditions that are linked
epidemiologically and apparently also at a molecular level.
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